NBTXR3 is designed to disrupt outcomes without disrupting clinical practice
Single Treatment
One-time intratumoral administration
Significantly enhances therapeutic index of radiotherapy
Easily Integrated into Patient Flow
Activated by any form of radiotherapy using standard equipment
Adds +1 visit to -50 visits in typical patient flow
Combinability with targeted therapies, chemotherapy and surgery
Well-Tolerated With Consistent Efficacy
Consistent overall response rate across all solid tumor indications evaluated to date
Does not change safety and tolerability of RT or immune checkpoint inhibitors
Over 300 patients with cancer treated to date
Broad Application
Universal application across all solid tumors
More than 60% of all cancer patients are treated with RT
Potential to expand and create new market opportunities with targeted therapeutics
NBTXR3 is being developed across solid tumor indications and therapeutic combinations, with an initial focus on locally advanced head and neck cancer
Indication
Trial Name
Approach
Phase 1
Phase 2
Phase 3
Expected Milestones
Head and NeckLocally Advanced
Nanoray-312
NBTXR3-RT*+-Cetuximab
Interim Ph3 Data2H 2024
Study 102
NBTXR3-RT*
Final Ph1 Data2H 2023
Head and NeckRecurrent And/Or Metastatic
TBD Planning
NBTXR3-RT*+ Anti-PD-1
Post new CMO review updateQ3 2023
Study 1100
NBTXR3-RT*+ Anti-PD-1
Expansion Data UpdateTBD
Completed Studies
Demonstrated Safety, Feasibility and Clinical Activityof NBTXR3-RT* Across Multiple Solid Tumors
Soft Tissue Sarcoma NBTXR3-RT*
Rectal** NBTXR3-RT* + Chemo Tx
Head and Neck** NBTXR3-RT* + Chemo Tx
Liver NBTXR3-RT*
Ongoing Studies
Exploring Safety, Feasibility and Efficacyof NBTXR3-RT* In Solid Tumors
Head and Neck NBTXR3-RT* + Anti-PD-1
Pancreatic NBTXR3-RT*
Esophageal NBTXR3-RT* + Chemo Tx
NSCLC NBTXR3-RT*
*NBTXR3-RT: NBTXR3 activated by radiotherapy; **Study terminated prior to completion as result of conclusion of collaboration, results presented at ASCO 22